Stockscreener 앱 받기
31.62
1.01%
0.341
전일 마감가:
$31.28
열려 있는:
$31.05
하루 거래량:
1.93M
Relative Volume:
0.46
시가총액:
$13.66B
수익:
$2.27B
순이익/손실:
$1.15B
주가수익비율:
12.40
EPS:
2.55
순현금흐름:
$2.80B
1주 성능:
-0.17%
1개월 성능:
-6.69%
6개월 성능:
+13.86%
1년 성능:
+9.70%
1일 변동 폭
$30.99
$31.76
1주일 범위
$30.64
$31.80
52주 변동 폭
$24.05
$34.20
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
31.63 | 13.66B | 2.27B | 1.15B | 2.80B | 2.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.67 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
621.35 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.34 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
260.88 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.41 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Trexquant Investment LP Raises Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Vanguard Group Inc. Has $952.90 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
(RPRX) Investment Analysis and Advice - news.stocktradersdaily.com
Is Royalty Pharma plc (RPRX) The Most Profitable Biotech Stock To Buy Right Now? - Insider Monkey
Korea Investment CORP Grows Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Norges Bank Takes Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Is Royalty Pharma Plc (RPRX) the Most Undervalued Healthcare Stock to Buy According to Analysts? - Yahoo Finance
Elo Mutual Pension Insurance Co Grows Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Sava Infond d.o.o. Purchases Shares of 21,000 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Sees Unusually Large Options Volume (NASDAQ:RPRX) - MarketBeat
8 Most Undervalued Healthcare Stocks to Buy According to Analysts - Insider Monkey
Brandywine Global Investment Management LLC Raises Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Homestead Advisers Corp Grows Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Corient Private Wealth LLC Purchases 21,383 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
7 Most Profitable Biotech Stocks To Buy Right Now - Insider Monkey
Royalty Pharma (NASDAQ:RPRX) Sees Strong Trading VolumeHere's Why - MarketBeat
KLP Kapitalforvaltning AS Invests $3.15 Million in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Has $47.68 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Teacher Retirement System of Texas Raises Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Virtu Financial LLC Invests $467,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
4 Healthcare Stocks With Massive Gains—and More to Come - Benzinga
Royalty Pharma pullback a buying opportunity, says Citi - TipRanks
UBS maintains neutral Royalty Pharma stock with $33 target By Investing.com - Investing.com UK
UBS Reiterates Neutral Rating on Royalty Pharma (RPRX) - StreetInsider.com
Citi maintains Buy on Royalty Pharma stock with $40 target By Investing.com - Investing.com UK
Royalty Pharma Announces Upcoming Investor Day - The Manila Times
Citi Reiterates Buy Rating on Royalty Pharma (RPRX) - StreetInsider
Royalty Pharma's Investor Day: Strategic Roadmap for Biopharma Innovation Funding - Stock Titan
Royalty Pharma plc (NASDAQ:RPRX) Stake Boosted by Royal London Asset Management Ltd. - MarketBeat
Thrivent Financial for Lutherans Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Proficio Capital Partners LLC Invests $786,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Fox Run Management L.L.C. Purchases 16,084 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Sciencast Management LP Invests $998,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Is Royalty Pharma plc (RPRX) The Best Defensive Stock Amid Market Volatility? - Yahoo Finance
15 Best Defensive Stocks Amid Market Volatility - Insider Monkey
Koss Olinger Consulting LLC Makes New $269,000 Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by HighTower Advisors LLC - MarketBeat
(RPRX) Technical Data - Stock Traders Daily
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.01%
자본화:
|
볼륨(24시간):